Zura Bio Ltd (ZURA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 25, 2025, and signed July 1, 2025, discloses significant executive leadership changes at Zura Bio Limited, a Cayman Islands-based emerging growth company. The filing details the appointment of a new Chief Financial Officer (CFO) and the resignation of the incumbent CFO.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. It focuses exclusively on executive compensation and severance arrangements:
- New CFO Compensation (Eric Hyllengren):
- Annual Base Salary: $475,000.
- Target Annual Cash Bonus: 40% of base salary ($190,000).
- Equity Grant: Option to purchase 672,000 Class A ordinary shares, vesting over 4 years (25% cliff, then quarterly).
- Outgoing CFO Severance (Verender Badial):
- Cash Severance: £178,294.92.
- Notice Payment: £89,147.46.
- Accrued Holiday Pay: £23,500.11.
- Health Insurance: £4,000.
- Transition Assistance: Up to £27,000.
- Equity Acceleration: Accelerated vesting of options covering 186,561 shares (107,811 + 78,750).
- Forfeiture: Options covering 303,100 shares granted on May 8, 2025, will be forfeited.
Material Changes
The primary material change is the transition of the Chief Financial Officer role:
- Departure: Verender Badial resigned as CFO, effective July 7, 2025. He will remain as a non-executive employee until July 31, 2025, to assist with the transition. The resignation is unrelated to financial results or accounting disagreements.
- Appointment: Eric Hyllengren was appointed CFO, effective July 7, 2025. He previously served as CFO and COO of Atara Biotherapeutics, Inc. and held leadership roles at Amgen Inc.
Outlook, Risks, and Contingencies
The filing does not provide updated financial guidance or discuss new business risks. Key contingencies include:
- Severance Conditions: All payments and benefits to Mr. Badial are contingent upon the effectiveness of the Settlement Agreement and his continued compliance, including a release of claims and non-disparagement provisions.
- Equity Restrictions: Shares acquired by Mr. Badial through accelerated vesting are subject to transfer restrictions (one-third annually over three years) without prior written consent.
- Indemnification: The Company has entered into a standard indemnification agreement with Mr. Hyllengren.
Investor Verification Checklist
- Verify the total cash outflow for Mr. Badial's severance by converting the GBP amounts to USD at the prevailing exchange rate.
- Review the full text of the Offer Letter (Exhibit 10.1) and Settlement Agreement (Exhibit 10.2) for any additional covenants or clawback provisions not summarized in the filing.
- Confirm the impact of the 303,100 forfeited options on the company's outstanding share count and dilution metrics.
- Monitor the press release (Exhibit 99.1) for any broader strategic context regarding the leadership change.